Reported about 23 hours ago
Novo Nordisk's stock saw an increase after UBS analysts upgraded it to a 'buy' rating, criticizing the recent sell-off as excessive. Although they lowered their price target due to concerns about patent expirations and disappointing trial results affecting future sales, analysts see the current price drop as an attractive entry point, especially as the weight-loss drug market is expected to improve this year.
Source: YAHOO